Raghda Al Anbari, MD
Internal Medicine · Athens, GANPI 1285164368
Payments from drug & device makers
Across 88 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$215
- Sanofi-aventis U.S. LLC$205
- Medtronic$201
- Lilly USA, LLC$173
- Amgen$144
- Radius Health, Inc.$114
- plus $703 from 19 others
What the payments were for
- Food & beverage$1,71398%
- Education$432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $215 |
| Sanofi-aventis U.S. LLC | 9 | $205 |
| Medtronic | 11 | $201 |
| Lilly USA, LLC | 7 | $173 |
| Amgen | 7 | $144 |
| Radius Health, Inc. | 5 | $114 |
| Xeris Pharmaceuticals, Inc. | 4 | $87 |
| Corcept Therapeutics | 4 | $83 |
| Abbott | 5 | $82 |
| Insulet Corporation | 3 | $55 |
| Boehringer Ingelheim | 3 | $52 |
| Tandem Diabetes Care, Inc. | 2 | $46 |
| Mannkind Corporation | 1 | $43 |
| AbbVie | 2 | $29 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $25 |
| Cequr Corporation | 1 | $23 |
| Pfizer | 1 | $23 |
| BETA Bionics, Inc. | 2 | $22 |
| Dexcom, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
How this compares
$1,756 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 246 | $349,855 |
| JardianceEmpagliflozin | 246 | $290,058 |
| OzempicSemaglutide | 135 | $271,096 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 172 | $147,785 |
| TymlosAbaloparatide | 36 | $125,124 |
| Humulin R U-500Insulin Regular, Human | 26 | $103,400 |
| TrulicityDulaglutide | 81 | $101,378 |
| ForteoTeriparatide | 13 | $70,478 |
| FarxigaDapagliflozin Propanediol | 65 | $69,690 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $51,092 |
| RybelsusSemaglutide | 30 | $47,680 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 48 | $46,880 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $35,188 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $29,618 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $21,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Baqsimi | $173 | $541,220412 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $215 | $343,204217 claims |
| Boehringer IngelheimJardiance | $52 | $290,058246 claims |
| Radius Health, Inc.Tymlos | $114 | $125,12436 claims |
| AstraZenecaFarxiga | $15 | $69,69065 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $205 | $46,88048 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $3,006277 claims |
| AbbVieSynthroid | $29 | $2,71527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Athens
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.